ONO Pharmaceutical Co ((OPHLF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ono Pharmaceutical Co. Ltd is conducting a Phase II clinical study titled ‘A Multicenter, Open-label, Phase II Pan-Tumor Study’ (ONO-4538-98) to evaluate the long-term safety of ONO-4538 in patients who have previously participated in trials involving this drug. The study aims to confirm the safety of ONO-4538, used alone or in combination with other therapies, in treating pan-tumor conditions.
The study tests ONO-4538, an experimental drug administered intravenously, either as monotherapy or in combination with other treatments like oxaliplatin, S-1, capecitabine, bevacizumab, and temozolomide. These interventions are designed to treat various tumor types effectively.
This interventional study employs a non-randomized, parallel assignment model with no masking, focusing primarily on treatment. The design allows for flexibility in treatment allocation, aiming to provide comprehensive safety data.
The study began on September 22, 2020, with an estimated primary completion date yet to be announced. The most recent update was submitted on June 1, 2025, indicating ongoing recruitment and data collection.
The continuation of this study could positively influence Ono Pharmaceutical’s stock performance by reinforcing investor confidence in ONO-4538’s potential. As the pharmaceutical industry remains competitive, successful outcomes could position Ono favorably against competitors.
The ONO-4538 study is actively recruiting, with further details available on the ClinicalTrials portal.